The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC).
C. Becerra
No relevant relationships to disclose
R. Salazar
No relevant relationships to disclose
R. Garcia-Carbonero
Consultant or Advisory Role - Amgen (B); Merck (B); Pfizer (B); Roche (B)
Honoraria - Amgen (B); Merck (B); Pfizer (B); Roche (B)
Research Funding - Amgen (B); Merck (B); Pfizer (B); Roche (B)
Other Remuneration - Amgen (B); Merck (B); Pfizer (B); Roche (B)
A. L. Thomas
No relevant relationships to disclose
F. Vázquez-Mazón
No relevant relationships to disclose
J. Cassidy
Research Funding - AstraZeneca
T. Maughan
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
M. Gallén
No relevant relationships to disclose
T. Iveson
Honoraria - Pfizer; Roche
Research Funding - Pfizer; Roche
Other Remuneration - Roche
M. Hixon
Research Funding - Pfizer
A. Gualberto
Research Funding - Pfizer
D. Yin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
E. K. Bergsland
No relevant relationships to disclose
D. Li
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer